scholarly journals Laparoscopic Resection of Primary Tumor with Synchronous Conventional Resection of Liver Metastases in Patients with Stage 4 Colorectal Cancer: A Retrospective Analysis

2019 ◽  
Vol 29 (1) ◽  
pp. 46-51
Author(s):  
Nuri Okkabaz ◽  
Mustafa C. Haksal ◽  
Mustafa Öncel
Keyword(s):  
Colorectal Cancer ◽  
Liver Metastases ◽  
Retrospective Analysis ◽  
Primary Tumor ◽  
Laparoscopic Resection ◽  
Stage 4

scholarly journals Discordance of KRAS Mutational Status between Primary Tumors and Liver Metastases in Colorectal Cancer: Impact on Long-Term Survival Following Radical Resection

Cancers ◽  
2021 ◽  
Vol 13 (9) ◽  
pp. 2148
Author(s):  
Francesco Ardito ◽  
Francesco Razionale ◽  
Lisa Salvatore ◽  
Tonia Cenci ◽  
Maria Vellone ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Liver Metastases ◽  
Primary Tumor ◽  
Kras Mutation ◽  
Colorectal Tumor ◽  
Term Survival ◽  
Primary Tumors ◽  
Mutation Status ◽  
Primary Colorectal Tumor ◽  
Kras Mutation Status

If KRAS mutation status of primary colorectal tumor is representative of corresponding colorectal liver metastases (CRLM) mutational pattern, is controversial. Several studies have reported different rates of KRAS discordance, ranging from 4 to 32%. Aim of this study is to assess the incidence of discordance and its impact on overall survival (OS) in a homogenous group of patients. KRAS mutation status was evaluated in 107 patients resected for both primary colorectal tumor and corresponding CRLM at the same institution, between 2007 and 2018. Discordance rate was 15.9%. Its incidence varied according to the time interval between the two mutation analyses (p = 0.025; Pearson correlation = 0.2) and it was significantly higher during the first 6 months from the time of primary tumor evaluation. On multivariable analysis, type of discordance (wild-type in primary tumor, mutation in CRLM) was the strongest predictor of poor OS (p < 0.001). At multivariable logistic regression analysis, the number of CRLM >3 was an independent risk factor for the risk of KRAS discordance associated with the worst prognosis (OR = 4.600; p = 0.047). Results of our study suggested that, in the era of precision medicine, possibility of KRAS discordance should be taken into account within multidisciplinary management of patients with metastatic colorectal cancer.

Benefits of simultaneous laparoscopic resection of primary colorectal cancer and liver metastases

2013 ◽  
Vol 7 (1) ◽  
pp. 31-37 ◽  
Author(s):  
Chie Takasu ◽  
Mitsuo Shimada ◽  
Hirohiko Sato ◽  
Tomohiko Miyatani ◽  
Satoru Imura ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Liver Metastases ◽  
Laparoscopic Resection ◽  
Primary Colorectal Cancer

scholarly journals Long-term follow-up of children with neuroblastoma receiving radiotherapy to metastatic lesions within the German Neuroblastoma Trials NB97 and NB 2004

2020 ◽  
Author(s):  
Danny Jazmati ◽  
Sarina Butzer ◽  
Barbara Hero ◽  
Jerome Doyen ◽  
Dalia Ahmad Khalil ◽  
...  
Keyword(s):  
Retrospective Analysis ◽  
Primary Tumor ◽  
Secondary Malignancy ◽  
Primary Tumor Site ◽  
Free Survival ◽  
Stage 4 ◽  
Metastatic Sites ◽  
The Impact

Abstract Purpose Neuroblastoma (NB) is the most common extracranial solid malignancy during childhood. Despite a multimodal treatment approach, the prognosis of patients with metastatic NB is not satisfactory. Although radiotherapy (RT) has become an integral part of treatment of the primary tumor, the role of RT in osteomedullary lesions is not well defined. A retrospective analysis was conducted to evaluate the impact of RT for metastatic sites in children with high-risk NB. Methods All patients with stage 4 NB from the prospective, multicenter NB trials NB97 and NB2004 who received RT to metastatic sites during frontline treatment were included in this retrospective analysis. Results A total of 18 children were irradiated with a median dose of 36 Gray (Gy; range 20–45 Gy) to one or more (range 1–3) osteomedullary metastases with or without concomitant RT to the primary tumor site. The median follow-up time was 149 months (range 55–220) in survivors. At 5 years, local relapse-free survival (LRFS) at irradiated metastatic sites and metastases-free survival (MFS) at distant, non-irradiated site rates were 51.4 and 39.9%, respectively. The estimated overall survival (OS) rate at 5 years was 49.4%. No high-grade acute or late toxicity and no secondary malignancy was reported. Conclusion RT to metastases is feasible for patients with stage 4 NB. However, an impact of RT to residual metastatic sites on outcome was not found. Studies with larger cohorts or prospective trials would be desirable in order to elucidate the role of RT for metastases.

scholarly journals Prognostic impact of primary tumor location in metastatic colorectal cancer (mCRC). A 5 year retrospective analysis of our treated population.

2017 ◽  
Vol 28 ◽  
pp. iii118-iii119
Author(s):  
Gonçalo Atalaia ◽  
Marta Vaz Baptista ◽  
Tiago Tomás ◽  
Susana Almeida ◽  
Inês Eiriz ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Retrospective Analysis ◽  
Primary Tumor ◽  
Tumor Location ◽  
Prognostic Impact ◽  
Primary Tumor Location

Primary tumor location impacts survival in colorectal cancer patients after resection of liver metastases

2020 ◽  
Vol 122 (4) ◽  
pp. 745-752
Author(s):  
Katherine Bingmer ◽  
Asya Ofshteyn ◽  
Jonathan T. Bliggenstorfer ◽  
William Kethman ◽  
John B. Ammori ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Liver Metastases ◽  
Cancer Patients ◽  
Primary Tumor ◽  
Tumor Location ◽  
Primary Tumor Location ◽  
Colorectal Cancer Patients

Retrospective analysis of pathologic response in colorectal cancer liver-only metastases following treatment with bevacizumab.

2012 ◽  
Vol 30 (4_suppl) ◽  
pp. 674-674
Author(s):  
Ruth Vera ◽  
Joan Figueras ◽  
Maria Luisa Gomez Dorronsoro ◽  
S. Lopez-Ben ◽  
Antonio Viúdez ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Liver Metastases ◽  
Retrospective Analysis ◽  
Hepatic Metastases ◽  
Stage Iv ◽  
Poor Response ◽  
Pathological Response ◽  
Residual Tumour ◽  
Tumour Location ◽  
Baseline Characteristics

674 Background: Recent reports have shown that pathological response predicts for better outcome (overall survival) following preoperative chemotherapy and surgical resection of colorectal cancer (CRC) liver-only metastases. The aim of this retrospective analysis was to evaluate the effect of adding bevacizumab to standard chemotherapy on pathological response in patients with CRC liver only metastases. Methods: Patients with stage IV CRC with liver metastases who received neoadjuvant chemotherapy (oxaliplatin-or irinotecan-based) at two Spanish centres were analysed retrospectively. Pathological response was evaluated as follows: complete pathological response (cPR), PR1 (25% of residual tumour), PR2 (25–50% of residual tumour), PR3 (>50% of residual tumour). cPR or PR1 was considered to be a good response, and PR2 or PR3 a poor response. Results: A total of 81 patients were evaluated. Of these, 43 received chemotherapy alone and 38 received chemotherapy plus bevacizumab. Baseline characteristics were as follows: median age 61.0 years (range 43.0–80.0 years); male/female (67%/33%); tumour location – colon (69%) / rectum (31%); hepatic metastases – synchronous (74%) / metachronous (26%); In terms of pathological response, 58% of patients receiving bevacizumab had a good response (cPR + PR1) compared with 28% of those receiving chemotherapy alone. At the end of the analysis, 68% of patients were still alive. Conclusions: Adding bevacizumab to oxaliplatin-based chemotherapy in the neoadjuvant setting improves the pathological response of liver metastases in patients with stage IV CRC. These findings indicate that pathological response might be a good indicator of outcome for patients receiving bevacizumab in the neoadjuvant setting.

Laparoscopic resection of colorectal cancer facilitates simultaneous surgery of synchronous liver metastases

2012 ◽  
Vol 15 (1) ◽  
pp. e21-e28 ◽  
Author(s):  
C. Hatwell ◽  
F. Bretagnol ◽  
O. Farges ◽  
J. Belghiti ◽  
Y. Panis
Keyword(s):  
Colorectal Cancer ◽  
Liver Metastases ◽  
Laparoscopic Resection ◽  
Synchronous Liver Metastases ◽  
Simultaneous Surgery

scholarly journals Metastatic colorectal cancer: What about the primary?

2012 ◽  
Vol 59 (2) ◽  
pp. 47-55
Author(s):  
Irinel Popescu ◽  
Tiberiu Alexandrescu
Keyword(s):  
Colorectal Cancer ◽  
Prognostic Factors ◽  
Survival Rate ◽  
Liver Metastases ◽  
Safety Profile ◽  
Primary Tumor ◽  
Survival Rates ◽  
Therapeutic Strategies ◽  
Unresectable Liver Metastases ◽  
Synchronous Metastases

Background: Approximately 25% of patients with colorectal cancer present synchronous metastases, most frequently located in the liver. Aims: The assessment of optimal therapeutic strategies for the primary tumor in such patients. Methods: We analyzed the outcomes of 209 patients who underwent simultaneous or delayed resection of the primary tumor and liver metastases, the survival rates of patients with initially unresectable liver metastases that were rendered resectable, and the prognostic factors related to the primary tumor. Results: The outcomes of simultaneous resections were similar to those of delayed resection. In patients with initially unresectable liver metastases that were rendered resectable, the survival rates were similar to those of patients with initially resectable metastases. The survival rate of N2 patients was significantly lower than those of N1 and N0 patients. Conclusions: Simultaneous resection provides a safety profile and survival rate similar to that of delayed resection. The N category allows for prognostic estimation in metastatic colorectal patients.

Sign in / Sign up

Export Citation Format

Share Document